Prame looks like the real deal
But can the novel antigen be targeted effectively? Immatics reckons it can, with the right dose and the right manufacturing process.
Fourth-quarter data for the little guys
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Esmo 2022 movers – Kras backfires
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Newamsterdam braves the Spac track
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.
Crunch time for the Spac space
This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.
Adicet scores the first hit for gamma-delta
Three of four lymphoma patients given ADI-001 go into remission, and Adicet soars 30%.
